

# Rewiring The Brain To Silence Food Noise

Written by The Life Science Feed Editorial Team · Published 28 May 2026 · Edited by Sarah Mitchell

## EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

## REFERENCES

1. Pi-Sunyer X, Astrup A, Fujioka K, et al. (SCALE Obesity and Prediabetes NN8022-1839 Study Group). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *\*N Engl J Med.\** 2015;373(1):11–22. [doi:10.1056/NEJMoa1411892](https://www.nejm.org/doi/full/10.1056/NEJMoa1411892)
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). *\*N Engl J Med.\** 2021;384:989–1002. [doi:10.1056/NEJMoa2032183](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183)
3. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. *\*Lancet.\** 2023;402:705–719. [doi:10.1016/S0140-6736(23)01185-6](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/abstract)
4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). *\*N Engl J Med.\** 2021;385:503–515. [doi:10.1056/NEJMoa2107519](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519)
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). *\*N Engl J Med.\** 2022;387:205–216. [doi:10.1056/NEJMoa2206038](https://www.nejm.org/doi/full/10.1056/NEJMoa2206038)
6. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *\*Lancet.\** 2023;402:613–626. [doi:10.1016/S0140-6736(23)01200-X](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/abstract)
7. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus Insulin Lispro Added to Basal Insulin in Type 2 Diabetes (SURPASS-6). *\*JAMA.\** 2023;330(18):1739–1750. [doi:10.1001/jama.2023.20294](https://pubmed.ncbi.nlm.nih.gov/37786396/)
8. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. *\*N Engl J Med.\** 2023;389:514–526. [doi:10.1056/NEJMoa2301972](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972)
9. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). *\*N Engl J Med.\** 2023;389:2221–2232. [doi:10.1056/NEJMoa2307563](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)

## LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

## MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

## FOLLOW THE LIFE SCIENCE FEED

**Instagram** @lifesciencefeed    **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com